Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 13, 2013, Pages 3732-3737

  Hwang, Sung Hee ^a   Wecksler, Aaron T ^a   Zhang, Guodong ^a   Morisseau, Christophe ^a   Nguyen, Long V ^a   Fu, Samuel H ^a   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; C RAF kinase; Regorafenib; Soluble epoxide hydrolase (sEH); Sorafenib; VEGFR 2

Indexed keywords

ANGIOGENESIS INHIBITOR; EPOXIDE HYDROLASE; HYDROLASE INHIBITOR; RAF PROTEIN; REGORAFENIB; SORAFENIB; SUNITINIB; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CANCER CELL; CELL PROLIFERATION; CHEMICAL MODIFICATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; LIVER CANCER; STRUCTURE ACTIVITY RELATION;

CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EPOXIDE HYDROLASES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MOLECULAR STRUCTURE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRIDINES; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84878848364     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.05.011     Document Type: Article

References (41)

1. A.A. Spector, X. Fang, G.D. Snyder, and N.L. Weintraub Prog. Lipid Res. 43 2004 55
2. C. Morisseau, and B.D. Hammock Annu. Rev. Pharmacol. Toxicol. 53 2013 37
3. A.A. Spector, and A.W. Norris Am. J. Physiol. Cell Physiol. 292 2007 C996
4. B. Inceoglu, S.L. Jinks, A. Ulu, C.M. Hegedus, K. Georgi, K.R. Schmelzer, K. Wagner, P.D. Jones, C. Morisseau, and B.D. Hammock Proc. Natl. Acad. Sci. U.S.A. 105 2008 18901
5. H.C. Shen, and B.D. Hammock J. Med. Chem. 55 2012 1789
6. A.C. Webler, U.R. Michaelis, R. Popp, E. Barbosa-Sicard, A. Murugan, J.R. Falck, B. Fisslthaler, and I. Fleming Am. J. Physiol. Cell Physiol. 295 2008 C1292
7. A. Oguro, K. Sakamoto, S. Suzuki, and S. Imaoka Biol. Pharm. Bull. 32 2009 1962
8. D.H. Munzenmaier, and D.R. Harder Am. J. Physiol. Heart Circ. Physiol. 278 2000 H1163
9. A. Pozzi, I. Macias-Perez, T. Abair, S. Wei, Y. Su, R. Zent, J.R. Falck, and J.H. Capdevila J. Biol. Chem. 280 2005 27138
10. Y. Wang, X. Wei, X. Xiao, R. Hui, J.W. Card, M.A. Carey, D.W. Wang, and D.C. Zeldin J. Pharmacol. Exp. Ther. 314 2005 522
11. A.L. Sander, K. Sommer, T. Neumayer, I. Fleming, I. Marzi, J. Frank, H. Jakob, and J.H. Barker Soluble epoxide hydrolase disruption as therapeutic target for wound healing J. Surg. Res. 182 2013 362 367
12. C. Zhang, and D.R. Harder Stroke 33 2002 2957
13. U.R. Michaelis, B. Fisslthaler, M. Medhora, D. Harder, I. Fleming, and R. Busse FASEB J. 17 2003 770
14. I. Fleming Prostaglandins Other Lipid Mediat. 82 2007 60
15. D. Panigrahy J. Clin. Invest. 122 2012 178
16. P. Cohen Nat. Rev. Drug Disc. 1 2002 309
17. J. Zhang, P.L. Yang, and N.S. Gray Nat. Rev. Cancer 9 2009 28
18. T.B. Loweinger, B. Riedl, J. Dumas, and R.A. Smith Curr. Pharm. Des. 8 2002 2269
19. D. Strumberg Drugs Today (Barc.) 41 2005 773
20. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J.F. Blanc, A.C. de Oliveira, A. Santoro, J.L. Raoul, A. Forner, M. Schwartz, C. Porta, S. Zeuzem, L. Bolondi, T.F. Greten, P.R. Galle, J.F. Seitz, I. Borbath, D. Häussinger, T. Giannaris, M. Shan, M. Moscovici, D. Voliotis, and J. Bruix N. Engl. J. Med. 359 2008 378
21. L. Rimassa, and A. Santoro Exp. Rev. Anticancer Ther. 9 2009 739
22. S. Wilhelm, C. Carter, M. Lynch, T. Lowinger, J. Dumas, R.A. Smith, B. Schwartz, R. Simantov, and S. Kelley Nat. Rev. Drug Disc. 5 2006 835
23. J.-Y. Liu, S.-H. Park, C. Morisseau, S.H. Hwang, B.D. Hammock, and R.H. Weiss Mol. Cancer Ther. 8 2009 2193
24. D. Strumberg, D. Voliotis, J.G. Moeller, R.A. Hilger, H. Richly, S. Kredtke, C. Beling, M.E. Scheulen, and S. Seeber Int. J. Clin. Pharmacol. Ther. 40 2002 580
25. Hammock, B. D.; Hwang, S. H.; Wecksler, A. T.; Morisseau, C. Sorafenib derivatives as soluble epoxide hydrolase inhibitors. WO2012112570 A1, Aug 23, 2012.
26. S.H. Hwang, H.-J. Tsai, J.-Y. Liu, C. Morisseau, and B.D. Hammock J. Med. Chem. 50 2007 3825
27. S. Ramurthy, S. Subramanian, M. Aikawa, P. Amiri, A. Costales, J. Dove, S. Fong, J.M. Jansen, B. Levine, S. Ma, C.M. McBride, J. Michaelian, T. Pick, D.J. Poon, S. Girish, C.M. Shafer, D. Stuart, L. Sung, and P.A. Renhowe J. Med. Chem. 51 2008 7049
28. D. Bankston, J. Dumas, R. Natero, B. Riedl, M.-K. Monahan, and R. Sibley Org. Process Res. Dev. 6 2002 777
29. T. Kasagami, I.-H. Kim, H.-J. Tsai, K. Nishi, B.D. Hammock, and C. Morisseau Bioorg. Med. Chem. Lett. 19 2009 1784
30. P.T. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, V.M. Good, C.M. Jones, C.J. Marshall, C.J. Springer, D. Barford, and R. Marais Cell 116 2004 855
31. T.B. Lowinger, B. Riedl, J. Dumas, and R.A. Smith Curr. Pharm. Design 8 2002 2269
32. I.H. Kim, C. Morisseau, T. Watanabe, and B.D. Hammock J. Med. Chem. 47 2004 2110
33. I.-H. Kim, H.-J. Tsai, K. Nishi, T. Kasagami, C. Morisseau, and B.D. Hammock J. Med. Chem. 50 2007 5217
34. S. Esser, M.G. Lampugnani, M. Corada, E. Dejana, and W. Risau J. Cell Sci. 111 1998 1853
35. S.M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J.M. Llovet, and M. Lynch Mol. Cancer Ther. 7 2008 3129
36. A.E. Enayetallah, R.A. French, M.S. Thibodeau, and D.F. Grant J. Histochem. Cytochem. 52 2004 447
37. K.F. Chen, W.T. Tai, J.W. Huang, C.Y. Hsu, W.L. Chen, A.L. Cheng, P.J. Chen, and C.W. Shiau Eur. J. Med. Chem. 46 2011 2845
38. A.P. Rebocho, and R. Marais Cancer Discov. 1 2011 98
39. F. Lovering, J. Bikker, and C. Humblet J. Med. Chem. 52 2009 6752
40. G. Zhang Proc. Natl. Acad. Sci. U.S.A. 2013 10.1073/pnas.1304321110
41. A. Zambon, I. Niculescu-Duvaz, D. Niculescu-Duvaz, R. Marais, and C.J. Springer Bioorg. Med. Chem. Lett. 22 2012 789